Navigation Links
Pharmaceutical Product Commercialization: Enabling Teams to Excel
Date:11/9/2007

CHAPEL HILL, N.C., Nov. 9 /PRNewswire/ -- Pharmaceutical product teams have the power to make or break the launch of a new product. The problem is launch teams often lack the right structure, tools and processes to run effectively and therefore only produce a sub-optimal launch.

In fact, pharmaceutical marketing and HR executives agree that collaborative behavior and cross-functional team work are key ingredients during product commercialization. According to a study by pharmaceutical benchmarking firm Best Practices, LLC, many organizations still use fully operational cross-functional teams too infrequently.

Cross-function collaboration is greatly improved through many methods -- structuring jobs with overlapping responsibilities, basing rewards on group performance, designing procedures so that employees with different jobs are better able to collaborate, and laying out work areas so that people can see one another's work and share lessons learned.

"Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence," available with a complimentary study summary online at http://www3.best-in-class.com/rr878.htm, provides extensive insight into how pharmaceutical, biotech and medical device companies are building team communication and leadership structures that prepare employees to excel in a competitive marketplace.

Valuable best practices and operating tactics were gathered from leading pharmaceutical companies, including Amgen, Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi-Aventis and Wyeth. They will help executives build and manage strong teams that can excel across functions, units and regions.

-- One benchmark partner aligned clinical and commercial's compensation,

bonuses and evaluation and saw a more unified approach to development

from the clinical and commercial sides. The alignment emphasizes the

goal of market success over any one functional activity.

-- The change came after the company found that its incentive programs

were major obstacles to the commercialization of the development

process. Scientists were rewarded for the number of INDs and NDAs they

submitted and cycle time for submission and approval. Marketing team

members were measured by market share and total sales.

-- While these two outlooks quite often conflict, eliminating sources of

friction in the incentives program has helped both groups work more

effectively to produce one of the company's recent successes.

For additional sample practices and metrics, download the free study summary at http://www3.best-in-class.com/rr878.htm.

This benchmarking report highlights the following areas of cross-functional team management:

-- Cross-Functional Team Structures

-- Collaboration and Productivity Processes

-- People Management

-- Decision-Making Processes

-- Communication and Collaboration

-- Resource Allocation

Download the complimentary excerpt at http://www3.best-in-class.com/rr878.htm or contact our Solution Specialists at (919) 403-0251 or bestpractices@best-in-class.com for more information.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant ... produce more and better food, with fewer resources. It highlights the business’ principles, ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... proud to announce that it has received 510(k) clearance from the U.S. Food ... and the MyoCycle Pro. , Both devices are stationary cycling systems that use ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges the ... how his administration could impact the employee benefits industry. James Slotnick, AVP, Government ... likely to make it through Congress. His discussion will focus on the current ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology: